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Glanzmann thrombasthenia (GT) is an inherited genetic disorder affecting
platelets, which is characterized by spontaneous mucocutaneous bleeding
and abnormally prolonged bleeding in response to injury or trauma. The
underlying defect is failure of platelet aggregation due to qualitative and/or
quantitative deficiency of platelet integrin αIIbβ3 resulting from molecular
genetic defects in either ITGA2B or ITGB3. Here, we examine a Pakistani
cohort of 15 patients with clinical symptoms of GT who underwent
laboratory and molecular genetic analysis. In patients with a broad range of
disease severity and age of presentation, we identified pathogenic mutations
in ITGA2B in 11 patients from 8 different families, including 2 novel
homozygous mutations and 1 novel heterozygous mutation. Mutations in
ITGB3 were identified in 4 patients from 3 families, two of which were novel
homozygous truncating mutations. A molecular genetic diagnosis was
established in 11 families with GT, including 5 novel mutations extending
the spectrum of mutations in this disease within a region of the world where
little is known about the incidence of GT. Mutational analysis is a key
component of a complete diagnosis of GT and allows appropriate
management and screening of other family members to be performed.
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Glanzmann thrombasthenia (GT) is a rare mucocuta-
neous bleeding disorder with an autosomal recessive
inheritance, first identified by Eduard Glanzmann in
1918 (1). Symptoms of spontaneous bleeding vary in fre-
quency and intensity among GT patients (2). Frequently,
petechiae, purpura and easy bruising are observable fea-
tures at birth (3), allowing an early clinical diagnosis.
Recurrent epistaxis, gingival bleeding and menorrhagia
(in females of child bearing age) are common symptoms
while gastrointestinal bleeding, intracranial hemorrhage
and hematuria have a lower incidental rate (2). In patients
with GT, there is an increased bleeding risk after surgery
and even dental procedures. Increased bleeding follow-
ing accidents and traumamay also create major problems
(4). Typically, the platelet count is normal (5) and platelet
size remains normal in most patients, although cases
with moderate thrombocytopenia and enlarged platelets
have been reported (6). The combination of mucocuta-
neous bleeding, an absence of platelet aggregation and
abnormal clot retraction associatedwith a normal platelet
count and morphology, is diagnostic for GT (7).
Mutations in ITGA2B or ITGB3 may lead to GT type
I or type II, where the expression of integrin αIIbβ3 at
the platelet surface is reduced (respectively less than
5% and 20% of normal). In contrast, in variant form of
GT there is a functional defect of the integrin αIIbβ3
complex (8). Both ITGA2B and ITGB3 are located on
chromosome 17 and encode the platelet integrin αIIbβ3,
previously known as glycoprotein IIb/IIIa. Platelet
aggregation is mediated by integrin αIIbβ3, an essential
receptor for platelets. Normally, during platelet activa-
tion, the integrin αIIbβ3, binds fibrinogen, which leads to
platelet aggregation (9). In GT, the process of thrombus
formation fails and clot retraction is also affected (9).
In patients suspected of GT, a deficiency of integrin
αIIbβ3 can be confirmed using flow cytometry or western
blotting withmonoclonal antibodies that recognize either
the αIIb, or β3 subunits or the αIIbβ3 complex (2).
Genetic analysis allows a definitive confirmation of
diagnosis. Both ITGA2B and ITGB3 are polymorphic and
are susceptible to germline mutations which occur more
frequently in ITGA2B.
GT is a rare disease, occurring at a ratio of approx-
imately 1:1,000,000, however it is more prevalent in
certain ethnic groups (10). In this study, we analyze a
cohort of 15 patients from Pakistan (from 11 different
families) with GT in whom we have made a molecu-
lar genetic diagnosis. We found three novel mutations in
ITGA2B and two novel mutations in ITGB3 extending the
molecular diagnosis in this previously uncharacterized
population.
Materials and methods
Patients and families
A total of 15 subjects with GT from 11 different families
were investigated in the study. Informed consent was
obtained from all patients and relatives according to a
protocol approved by the National Institute of Blood
Disease & Bone Marrow Transplantation, Karachi,
Pakistan. Medical histories of patients were recorded
in a questionnaire, which included age, gender, age
at onset, consanguineous marriage between parents,
a family history of bleeding, severity of bleeding and
hemorrhagic clinical symptoms.
Hematological and molecular analysis
GT patients were screened based on platelet counts
and morphology. Platelet aggregation tests were per-
formed on a Helena AggRAM (Helena Laboratories,
Beaumont, Texas, USA) using ristocetin, epinephrine,
adenosine diphosphate (ADP) and collagen. Bleeding
time (BT) measurements were performed and com-
pared with reference values: 0–4 years, 4± 1min;
boys >4 years, 5± 1min; girls >4 years, 5.5± 1min.
Genomic DNA was extracted from peripheral blood
leukocytes isolated from whole blood obtained from
patients and (where available) parents. Exon poly-
merase chain reaction (PCR) was used to amplify all
coding regions of the ITGA2B and ITGB3 genes (using
reference sequences NM_000419 and NM_000212,
respectively). PCR products were purified and
Sanger sequenced. Segregation using parental sam-
ples was undertaken when available. MutationTaster™
(http://www.mutationtaster.org/) and PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/index.shtml) were used
to determine pathogenicity of novel mutations. The
crystal structure of the complete ectodomain of integrin
αIIbβ3 (PDB code 3FCS) (11, 12) was visualized using
PyMOL (http://pymol.org/) to identify the position of
the missense mutations identified in the present study.
Results
Clinical and laboratory findings
A total of 15 GT patients from 11 consanguineous Pak-
istan families were evaluated in this study (Table 1). The
age of the patients ranged from 1 to 16 years with an age
of disease onset ranging from 7 days to 4 years (mean age
of onset of 2 years). Fifty percentage of patients had a
positive family history of a bleeding disorder. Common
clinical symptoms included recurrent epistaxis and gin-
gival bleeding (73%), and easy bruising (67%) (Table 1).
Gastrointestinal hemorrhage (four cases), petechiae and
purpura (two cases) and hemathrosis (one case) were
rare. BT was prolonged in all of our patients and was
often over 10min, while activated partial thromboplas-
tin time (APTT) and prothrombin time (PT) remained
within normal range in 14 (93%) and 13 (87%) patients,
respectively. Platelet aggregation assays for all cases
measured were defective when using ADP, adrenaline,
collagen and arachidonic acid. These findings are typical
of GT, as platelet aggregation tends to be defective with
all agonists. The response to ristocetin was maintained
in 13 of 14 patients tested and platelet count was within
normal limits for all patients except one (Table 1).
Genetic findings
We identified 7 different mutations in ITGA2B
in 11 patients (from 8 families). Three of these
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Table 1. Clinical and laboratory findings in the GT cohort
Patient ID A B C D E F G H I J K L M N O
Family number 1 2 3 3 4 5 6 7 8 8 8 9 9 10 11
Age (years), sex 6, M 16, M 12, M 10, M 1, F 16, F 1, F 8, F 3, F 5, F 5, M 10, F 15, F 7, M 7, F
Age at onset 4.5 y 5 d 2 y 1 y 3m 12 y 6m 6m 3m 6m 7 d 4 y 4 y 1 y 1 y
Clinical symptoms
Petechiae and purpura − − − − − − − − + − − − − + −
Easy bruising + − − − + + + + + + + + + + −
Recurrent epistaxis − + − + − + + + + + + − + + +
Gingival bleeding − + − − + + + + − + + + + + +
Gastrointestinal bleeding + − − − − − − + − + + − − − −
Intracranial hemorrhage − − − − − − − − − − − − − − −
Hematuria − − − − − − − − − − + − − − −
Hemorrhage after dental − − − − − − − + − − − − − + −
Hemorrhage after trauma − − − − − − − + − + + − − + −
Ear bleeding − − − − − − + + − − + − − − −
Hemarthrosis − − − − − − − + − − − − − − −
Hematemesis − − − − − − − − − − − − − − −
Hematoma − − + − − − − − − + + − − − −
Bleeding time (min) (for NR see Methods) 10 7 10 N/A >10 N/A >10 >10 >10 10 10 10 >10 >10 N/A
APTT (s) (NR 27–35) 29 28 28 26 28 38 29 29 30 28 29 29 25 25 30
PT (s) (NR 12–13) 12.5 14 12 11.5 12 16 12.5 11.5 11.5 13 11 12 13 12 12
Platelet aggregation assay
ADP X X X N/A X X X X X X X X X X X
Adrenaline X X X N/A X X X X X X X X X X X
Collagen X X X N/A X X X X X X X X X X X
Arachidonic acid X X N/A N/A X X X X X X X X X X X
Ristocetin N N N N/A N N X N N N N N N N N
Hematological evaluation
Platelet count (× 109/l) (NR 150–450) 371 205 156 150 212 235 407 312 212 129 272 225 199 250 301
Red blood cell count (× 106/ml) 3.9 3.7 3.4 3.7 3.2 2.5 4.12 3.93 3.69 3.1 3.57 3.2 3.5 2.6 3.8
Family history of bleeding − + − N/A − − + − + + + + + − −
+, present; −, absent; ADP, adenosine diphosphate; d, day; F, female; GT, Glanzmann thrombasthenia; m, month; M, male; min,
minutes; N, normal; N/A, not available; NR, Normal range; s, second; X, defective; y, year. Abnormal results are shown in bold.
mutations in this gene (p.N145K, p.S477Gfs*111
and p.N536Kfs*29) were novel (Table 2) and were not
found on database searches including 1000 Genomes
(http://www.1000genomes.org/), Exome Variant Server
(http://evs.gs.washington.edu/EVS/) and the GT
database (http://sinaicentral.mssm.edu/intranet/research/
glanzmann/menu). One patient (A, Family 1) had com-
pound heterozygous mutations which included the novel
missense change p.N145K together with a nonsense
mutation, p.C177* previously reported by Jallu et al. (in
its homozygous state) in a GT patient from China (13).
Unfortunately, parental samples were unavailable to
confirm segregation, but given the negative family his-
tory of GT in this family, it is possible that one of these
mutations may have occurred de novo. The remaining
patients had homozygous mutations, in keeping with
known consanguinity. Mutations included p.L214R,
which has been previously reported and investigated
in terms of its pathogenicity (14). The nonsense muta-
tion p.Y411* found in two siblings of Family 3 and
is predicted to lead to a severe truncation of the αIIb
protein. This mutation has previously been reported in
a heterozygous state (in combination with a p.V329F
missense mutation) in a 1-year-old child with GT (15).
Both p.S477Gfs*111 (Family 4) and p.N536Kfs*29
(Family 5), secondary to a small insertions/deletions,
respectively, were novel mutations and were predicted
to disrupt the extracellular thigh domain of integrin αIIb
(Fig. 1, Table 2). The previously reported R551Q mis-
sense mutation which caused severe disease at birth in an
Indian child (16) was present in five patients from three
different families (Fig. 1, Table 2). The presentation of
these cases was between 7 days of age and 6months
of age.
We identified three different mutations in ITGB3 in
four patients (from three families) which are predicted
to affect the integrin beta subunit (Fig. 1, Table 2).
All mutations in ITGB3 were homozygous and two
mutations were novel nonsense mutations (p.C258* and
p.Q694*) not found in database searches. The L143W
mutation in ITGB3 was found in two patients, and has
been previously described in a patient also from Pakistan
(17) and in two patients from India (18).
Discussion
GT is an autosomal recessively inherited platelet func-
tion disorder that appears to be more common in areas
with high consanguinity rate. Consanguineous unions
are commonly seen among Pakistanis, as in other ethnic
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Fig. 1. Molecular modeling of missense mutations affecting the inte-
grin αIIbβ3 complex. Crystal structure of the αIIbβ3 ectodomain
[PDB:3FCS]. The domains are color-coded to match the schematic
(inset) showing the complete integrin structure. Ca2+ and Mg2+ ions are
represented as yellow and gray spheres, respectively. Themutations iden-
tified in this study are highlighted as red spheres.
groups including Iraqi Jews, Northern Iranians, South-
ern Indians, Jordanians, Saudi Arabians and Arabs living
in Israel. The Pakistan Demographic and Health Survey
revealed that two thirds of marriages in Pakistan are con-
sanguineous, promoting increased rates of rare autoso-
mal recessive disorders (19). In our study, all of the cases
were born to consanguineous parents.
Most of the GT cases are diagnosed clinically at an
early age. Our study had an age of presentation from
7 days to 4 years and half of the patients had a history of
severe bleeding. All our patients with GT showed typical
defective platelet aggregometry in response to the ago-
nists used. A differential diagnosis, especially in older
patients, would include the development of inhibitory
anti-αIIbβ3 autoantibodies that cause an acquired throm-
basthenia (20). Leukemia may also present in a similar
manner in later life and investigations of platelet func-
tion should be performed in a systematic fashion. Finally,
there are reports of an autosomal dominant GT-like
syndrome which displays macrothrombocytopenia (21).
Platelet counts were decreased in one of our patients and
two patients had prolonged PT. Some molecular defects
in GTmay affect platelet production, such as the R560B3
defect that was recently modeled in vivo (22).
We identified a wide spectrum of mutations within
ITGA2B and ITGB3. Several families identified here
had novel ‘private’ mutations, emphasizing a need to
sequence the entire coding regions of both genes. The
establishment of infrastructures to allow such molecular
genetic diagnostics in remote regions of the world, where
consanguinity rates are high, would be a real advance.
Integrins have two subunits, alpha and beta and form
an obligate heterodimer (Fig. 1). In mammals, there
are 18 different alpha and 8 different beta subunits.
Integrin subunits penetrate the plasma membrane and
have short (40–70 amino acid) cytoplasmic domains
(23). The integrin αIIbβ3 complex is formed from a
calcium-dependent association of glycoprotein IIb and
IIIb. The crystal structure of integrin αIIbβ3 has been
described (11, 12). Mapping of known mutations to
the functional domains of the integrin αIIbβ3 complex
shows that a broad range of mutations exists and that
genotype/phenotype correlations are difficult within this
complex molecular structure.
Conclusion
GT occurs in high frequency in certain ethnic popula-
tions with an increased incidence of consanguinity. GT
is caused by mutations in the genes encoding ITGA2B or
ITGB3 that result in qualitative or quantitative abnormal-
ities in the platelet membrane proteins leading to bleed-
ing disorders. A precise molecular diagnosis in patients
with suspected GT allows an increased understanding of
the disease pathogenesis, and is important for screen-
ing of at risk family members and establishing a pre-
natal diagnosis. Here, we have successfully identified
pathogenic mutations in either ITGA2B or ITGB3 in 15
patients with GT from a previously uncharacterized eth-
nic group and country, where little is known about the
incidence and molecular genetics of GT.
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